BACKGROUND: Ischemic heart disease is a leading cause of heart failure and despite advanced therapeutic options, morbidity and mortality rates remain high. Although acute inflammation in response to myocardial cell death has been extensively studied, subsequent adaptive immune activity and anti-heart autoimmunity may also contribute to the development of heart failure. After ischemic injury to the myocardium, dendritic cells (DC) respond to cardiomyocyte necrosis, present cardiac antigen to T cells, and potentially initiate a persistent autoimmune response against the heart. Cross-priming DC have the ability to activate both CD4+ helper and CD8+ cytotoxic T cells in response to necrotic cells and may thus be crucial players in exacerbating autoimmunity targeting the heart. This study investigates a role for cross-priming DC in post-myocardial infarction immunopathology through presentation of self-antigen from necrotic cardiac cells to cytotoxic CD8+ T cells. METHODS: We induced type 2 myocardial infarction-like ischemic injury in the heart by treatment with a single high dose of the β-adrenergic agonist isoproterenol. We characterized the DC population in the heart and mediastinal lymph nodes and analyzed long-term cardiac immunopathology and functional decline in wild type and Clec9a-depleted mice lacking DC cross-priming function. RESULTS: A diverse DC population, including cross-priming DC, is present in the heart and activated after ischemic injury. Clec9a-/- mice deficient in DC cross-priming are protected from persistent immune-mediated myocardial damage and decline of cardiac function, likely because of dampened activation of cytotoxic CD8+ T cells. CONCLUSION: Activation of cytotoxic CD8+ T cells by cross-priming DC contributes to exacerbation of postischemic inflammatory damage of the myocardium and corresponding decline in cardiac function. Importantly, this provides novel therapeutic targets to prevent postischemic immunopathology and heart failure.
BACKGROUND: Ischemic heart disease is a leading cause of heart failure and despite advanced therapeutic options, morbidity and mortality rates remain high. Although acute inflammation in response to myocardial cell death has been extensively studied, subsequent adaptive immune activity and anti-heart autoimmunity may also contribute to the development of heart failure. After ischemic injury to the myocardium, dendritic cells (DC) respond to cardiomyocyte necrosis, present cardiac antigen to T cells, and potentially initiate a persistent autoimmune response against the heart. Cross-priming DC have the ability to activate both CD4+ helper and CD8+ cytotoxic T cells in response to necrotic cells and may thus be crucial players in exacerbating autoimmunity targeting the heart. This study investigates a role for cross-priming DC in post-myocardial infarction immunopathology through presentation of self-antigen from necrotic cardiac cells to cytotoxic CD8+ T cells. METHODS: We induced type 2 myocardial infarction-like ischemic injury in the heart by treatment with a single high dose of the β-adrenergic agonist isoproterenol. We characterized the DC population in the heart and mediastinal lymph nodes and analyzed long-term cardiac immunopathology and functional decline in wild type and Clec9a-depleted mice lacking DC cross-priming function. RESULTS: A diverse DC population, including cross-priming DC, is present in the heart and activated after ischemic injury. Clec9a-/- mice deficient in DC cross-priming are protected from persistent immune-mediated myocardial damage and decline of cardiac function, likely because of dampened activation of cytotoxic CD8+ T cells. CONCLUSION: Activation of cytotoxic CD8+ T cells by cross-priming DC contributes to exacerbation of postischemic inflammatory damage of the myocardium and corresponding decline in cardiac function. Importantly, this provides novel therapeutic targets to prevent postischemic immunopathology and heart failure.
Authors: Patrick Blanco; A Karolina Palucka; Virginia Pascual; Jacques Banchereau Journal: Cytokine Growth Factor Rev Date: 2008-02 Impact factor: 7.638
Authors: Eugenio Stabile; Timothy Kinnaird; Andrea la Sala; Sue Kim Hanson; Craig Watkins; Umberto Campia; Matie Shou; Stephan Zbinden; Shmuel Fuchs; Hardy Kornfeld; Stephen E Epstein; Mary Susan Burnett Journal: Circulation Date: 2005-12-27 Impact factor: 29.690
Authors: Elisa Martini; Paolo Kunderfranco; Clelia Peano; Pierluigi Carullo; Marco Cremonesi; Tilo Schorn; Roberta Carriero; Alberto Termanini; Federico Simone Colombo; Elena Jachetti; Cristina Panico; Giuseppe Faggian; Andrea Fumero; Lucia Torracca; Martina Molgora; Javier Cibella; Christina Pagiatakis; Jolanda Brummelman; Giorgia Alvisi; Emilia Maria Cristina Mazza; Mario Paolo Colombo; Enrico Lugli; Gianluigi Condorelli; Marinos Kallikourdis Journal: Circulation Date: 2019-10-30 Impact factor: 29.690
Authors: Elvira Forte; Daniel A Skelly; Mandy Chen; Sandra Daigle; Kaesi A Morelli; Olivia Hon; Vivek M Philip; Mauro W Costa; Nadia A Rosenthal; Milena B Furtado Journal: Cell Rep Date: 2020-03-03 Impact factor: 9.423
Authors: Jennifer C Miller; Brian D Brown; Tal Shay; Emmanuel L Gautier; Vladimir Jojic; Ariella Cohain; Gaurav Pandey; Marylene Leboeuf; Kutlu G Elpek; Julie Helft; Daigo Hashimoto; Andrew Chow; Jeremy Price; Melanie Greter; Milena Bogunovic; Angelique Bellemare-Pelletier; Paul S Frenette; Gwendalyn J Randolph; Shannon J Turley; Miriam Merad Journal: Nat Immunol Date: 2012-07-15 Impact factor: 25.606
Authors: Christoph Kuppe; Ricardo O Ramirez Flores; Zhijian Li; Sikander Hayat; Rebecca T Levinson; Xian Liao; Monica T Hannani; Jovan Tanevski; Florian Wünnemann; James S Nagai; Maurice Halder; David Schumacher; Sylvia Menzel; Gideon Schäfer; Konrad Hoeft; Mingbo Cheng; Susanne Ziegler; Xiaoting Zhang; Fabian Peisker; Nadine Kaesler; Turgay Saritas; Yaoxian Xu; Astrid Kassner; Jan Gummert; Michiel Morshuis; Junedh Amrute; Rogier J A Veltrop; Peter Boor; Karin Klingel; Linda W Van Laake; Aryan Vink; Remco M Hoogenboezem; Eric M J Bindels; Leon Schurgers; Susanne Sattler; Denis Schapiro; Rebekka K Schneider; Kory Lavine; Hendrik Milting; Ivan G Costa; Julio Saez-Rodriguez; Rafael Kramann Journal: Nature Date: 2022-08-10 Impact factor: 69.504